Table 2.
Univariate Analysis of Prognostic factors of BCSS and OS in Metastatic Breast Cancer
| Characteristic | BCSS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | p | HR | 95%CI | p | |
| Age | 1.017 | 1.015–1.018 | < 0.001 | 1.024 | 1.022–1.025 | < 0.001 |
| Race | ||||||
| White | 1 | 1 | ||||
| Black | 1.081 | 1.019–1.147 | 0.009 | 1.313 | 1.248–1.381 | < 0.001 |
| Others | 0.893 | 0.813–0.98 | 0.017 | 0.91 | 0.839–0.986 | 0.022 |
| Marital status | ||||||
| Married | 1 | 1 | ||||
| Unmarried | 1.235 | 1.177–1.297 | < 0.001 | 1.482 | 1.421–1.545 | < 0.001 |
| Grade | ||||||
| I | 1 | 1 | ||||
| II | 1.154 | 1.023–1.303 | 0.02 | 1.267 | 1.148–1.398 | < 0.001 |
| III & IV | 1.377 | 1.223–1.551 | < 0.001 | 1.824 | 1.656–2.008 | < 0.001 |
| BC Subtype | ||||||
| HR+/HER2- | 1 | 1 | ||||
| HR+/HER2+ | 1.025 | 0.949–1.108 | 0.528 | 0.816 | 0.763–0.873 | < 0.001 |
| HR−/HER2+ | 1.312 | 1.193–1.443 | < 0.001 | 1.115 | 1.027–1.212 | < 0.001 |
| Triple negative | 1.73 | 1.616–1.852 | < 0.001 | 2.539 | 2.395–2.691 | < 0.001 |
| Stage T | ||||||
| T0/T1 | 1 | 1 | ||||
| T2 | 0.917 | 0.841–1.001 | 0.052 | 1.002 | 0.935–1.074 | 0.96 |
| T3 | 0.92 | 0.836–1.012 | 0.085 | 1.104 | 1.021–1.194 | 0.013 |
| T4 | 1.149 | 1.058–1.248 | 0.001 | 1.493 | 1.397–1.595 | < 0.001 |
| Stage N | ||||||
| N0 | 1 | 1 | ||||
| N1 | 0.854 | 0.8–0.912 | < 0.001 | 0.892 | 0.845–0.942 | < 0.001 |
| N2 | 0.728 | 0.662–0.8 | < 0.001 | 0.845 | 0.779–0.918 | < 0.001 |
| N3 | 0.902 | 0.844–0.965 | 0.003 | 1.096 | 1.036–1.159 | 0.001 |
| Surgery | ||||||
| No | 1 | 1 | ||||
| Yes | 0.622 | 0.588–0.659 | < 0.001 | 0.513 | 0.489–0.538 | < 0.001 |
| Radiotherapy | ||||||
| No | 1 | 1 | ||||
| Yes | 0.754 | 0.717–0.793 | < 0.001 | 0.756 | 0.723–0.79 | < 0.001 |
| Chemotherapy | ||||||
| No/Unknown | 1 | 1 | ||||
| Yes | 0.655 | 0.625–0.686 | < 0.001 | 0.626 | 0.601–0.651 | < 0.001 |
| Metastatic site | ||||||
| Bone | 1 | 1 | ||||
| Lung | 1.319 | 1.214–1.434 | < 0.001 | 1.435 | 1.339–1.537 | < 0.001 |
| Liver | 1.365 | 1.242–1.5 | < 0.001 | 1.415 | 1.306–1.532 | < 0.001 |
| Brain | 1.708 | 1.442–2.023 | < 0.001 | 2.492 | 2.161–2.874 | < 0.001 |
| Other | 1.127 | 1.021–1.244 | < 0.001 | 1.285 | 1.187–1.392 | < 0.001 |
| Multiple | 1.484 | 1.405–1.567 | < 0.001 | 1.944 | 1.855–2.037 | < 0.001 |
Abbreviations: BCSS breast cancer–specific survival, OS overall survival, HR hazard ratio, CI confidence interval, BC breast cancer, HR hormone receptor, HER2 human epidermal growth receptor 2, TN triple negative